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The aim of this study was to evaluate sensitivity and speciﬁcity for reticulocyte hemoglobin content (CHr) compared to other
hematimetric and biochemical iron parameters, in particular, mean corpuscular hemoglobin (MCH), when screening for iron
deﬁciency in elderly anemic patients. Bone marrow staining negative for iron was used as the gold standard criterion for iron
deﬁciency anemia (IDA). Sensitivity and speciﬁcity for CHr, soluble transferrin receptor (sTfR), soluble transferrin receptor/log
ferritin (TfR-F index), ferritin, MCH, and transferrin saturation were determined. The best cut-oﬀ point for CHr was 30.5pg
corresponding to a sensitivity and speciﬁcity of 93% and 69% for IDA, respectively. For MCH, a sensitivity of 93% and a speciﬁcity
of 86%, respectively, correspond to an optimal cut-oﬀ of 28.5pg. Analysis of CHr was not superior to MCH with respect to
sensitivity and speciﬁcity when screening for IDA in elderly anemic patients.
1.Introduction
Iron deﬁciency anemia is often a challenge to diagnose using
noninvasive methods in elderly anemic patients with comor-
bid conditions such as cancer, infections, or inﬂammatory
diseases, since biochemical iron status is inﬂuenced by acute-
phase responses [1]. Under these circumstances the best
way to discriminate between IDA and anemia induced by
an acute-phase response, that is, anemia of chronic disease
(ACD), is to perform a bone marrow examination [2]. In
contrast to ACD, there is no stainable bone marrow iron in
IDA. The erythrocyte has a lifespan of approximately 120
days in the circulation, which means that the parameter
MCH is a measure of the of the iron availability for
the erythropoiesis during this time period. In contrast
to this, CHr gives a snapshot of the iron availability for
erythropoiesis, since the lifespan of the reticulocyte is just
1-2 days [3]. Thus, a decrease in reticulocyte hemoglobin
content precedes a similar decrease in erythrocytes and is
an early and reliable indicator of iron deﬁciency anemia
[4, 5]. CHr, not being aﬀected by acute phase responses, is
also an early indicator of functional iron deﬁciency (FID) in
patientstreatedwitherythropoietic stimulating agents[6,7].
Previous studies assessing a role for CHr in diagnosing iron
deﬁciency have not used the lack of stainable bone marrow
iron as the gold standard criterion for iron deﬁciency or
if so, only a fraction of the examined patients have been
anemic [4–8]. In the study reported here, where the aim
was to evaluate a role for CHr in the diagnosis of iron
deﬁciency, all patients examined were anemic and the gold
standard criterion for iron deﬁciency was lack of stainable
bone marrow iron.
2.MaterialandMethods
Sixty consecutive newly diagnosed anemic patients (Hb
<134g/L in men and <117g/L in women), 60 years of age
or older admitted to the Department of Medicine, Capio
Sankt G¨ orans Hospital, were screened. All procedures were
in accordancewiththe Helsinki Declaration of 1964. Patients
receiving iron supplementation or red cell transfusions were
excluded from the study. Those with leukemias, myeloma,
myelodysplastic syndromes, folate or coboalamin deﬁciency,
and hemolytic anemia were also excluded, whereas patients2 Anemia
with lymphomas without bone marrow involvement were
included.Ofthe60screenedpatients,6(10%)wereexcluded.
This observational study was performed on left-over blood
and bone marrow samples collected during routine anemia
investigation. A complete blood count, biochemical iron
status (serum iron, total iron binding capacity [TIBC],
transferrin saturation, ferritin), soluble transferrin receptor
(sTfR), reticulocyte hemoglobin content (CHr), and bone
marrow iron stores were analyzed in every patient. Transfer-
rin saturationiscalculatedbytheformula:serumiron/TIBC.
Bone marrow smears were stained by means of the May-
Grunwald-Giemsa method, and bone marrow iron stores
were investigated using Prussian blue staining. Patients with
nostainablebonemarrowironwerediagnosedashavingiron
deﬁciency anemia (IDA), whereas the diagnosis for those
with stainable iron was anemia of chronic disease (ACD).
Complete blood counts and CHr analysis were performed
using the ADVIA 2120 analyzer (Siemens Diagnostics,
Deerﬁeld, IL, USA). C-reactive protein (CRP), iron, and
TIBC were investigated by means of ADVIA 2400 and
sTfR using BN ProSpec (Siemens Diagnostics, Deerﬁeld,
IL, USA). Ferritin was analyzed using ADVIA Centaur XP
(Siemens Diagnostics, Deerﬁeld, IL, USA). All reagents were
from Siemens Diagnostics except for the TIBC assay, which
was from Dakopatts (Dakopatts, Dorchester, UK). In our
laboratory reference values for mean corpuscular volume
(MCV) are 82–98fL, mean corpuscularhemoglobin (MCH )
27–33pg, iron 9–34µmol/L, TIBC 47–80µmol/L, transferrin
saturation 15–60% for men and 10–50% for women, ferritin
20–375µg/L for men and 7–120µg/L for women, CRP<
5mg/L, soluble transferrin receptor 0.8–1.7mg/L, and CHr
24–36pg. All analyses were performed at the Department
of Clinical Chemistry, Capio Sankt G¨ orans Hospital, except
for the bone marrow analyses which were performed at the
Department of Pathology, Capio Sankt G¨ orans Hospital.
Statistical and Receiver Operation Characteristics (ROCs)
c u r v ea n a l y s e sw e r ep e r f o r m e du s i n gt h eS i g m a P l o t1 1
software package (Systat Software, San Jose, CA, USA).
Quantitative variables were expressed as means ± standard
deviations. The Student’s t test or Mann-Whitney rank sum
test was used to compare the variables between the two
groups. A P value less than 0.05 was considered statistically
signiﬁcant.
3. Results andDiscussion
Of the 54 patients studied, 14 (26%) were iron deplete as
determined by the absence of stainable bone marrow iron,
whereas 40 (74%) were iron replete (Table 1). The dominant
clinical diagnoses in the IDA group was benign gastrointesti-
nalhemorrhage(57%)andgastrointestinalhemorrhagewith
no source of blood loss identiﬁed (29%). In the ACD group,
the most common diagnoses were infections (21%), cancer
(18%), liver disease (18%), fever of unknown origin (13%),
and giant cell arteritis (13%). There was no signiﬁcant
diﬀerence in age between the two groups, with mean age of
76 and 79 years in the IDA and ACD groups, respectively
(Table 1) .T h em e a nv a l u e so fH b ,C H r ,M C V ,M C H ,i r o n ,
transferrin saturation, and ferritin were signiﬁcantly lower
Table 1: Comparison of hematimetric and biochemical iron
parameters and CRP between patients with IDA and ACD. Data
are expressed as means ± SD. IDA, iron deﬁciency anemia; ACD:
anemia of chronic Disease; CHr: reticulocyte hemoglobin content;
MCH: mean corpuscular hemoglobin; MCV: mean corpuscular
volume; TIBC: total iron binding capacity; TSAT: transferrin
saturation,sTfR:solubletransferrinreceptor;TfR-FIndex,sTfR/log
Ferritin; CRP, C-Reactive Protein.
Variable IDA ACD P
Age (years) 76 ±67 9 ±9 0.291
Hb (g/L) 83 ±23 100 ±13 0.012
CHr (pg) 25.9 ±3.93 1 .2 ±4.2 <0.001
MCH (pg) 24.6 ±4.33 0 .5 ±3.3 <0.001
MCV (fL) 80.2 ±10.49 4 .3 ±9.8 <0.001
Iron (µmol/L) 3.8 ±2.99 .4 ±8.7 <0.01
TIBC (µmol/L) 75.3 ±16.84 5 .4 ±17.2 <0.01
TSAT (%) 8.5 ±13.22 2 .7 ±2.2 <0.001
sTfR (mg/L) 3.45 ±1.67 1.41 ±0.56 <0.001
Ferritin (µg/L) 14 ±10 439 ±416 <0.001
TfR-F Index 3.62 ±3.21 0.69 ±0.38 <0.001
CRP (mg/L) 20 ±25 64 ±33 0.102
Table 2: Test characteristics based on optimal Cut-oﬀ Values for
IDA Screening Determined by ROC Curve Analysis. Abbreviations:
CHr, Reticulocyte Hemoglobin Content; MCH, Mean Corpuscular
Hemoglobin; TSAT, Transferrin Saturation; sTfR, Soluble Transfer-
rin Receptor; TfR-F Index, sTfR/log Ferritin; IDA, Iron Deﬁciency
Anemia; ROC, Receiver Operation Characteristics.
Variable Sensitivity (%) Speciﬁcity (%) Cut-oﬀ ROC area
CHr (pg) 93 69 30.5 0.84
MCH (pg) 93 86 28.5 0.91
TSAT (%) 93 57 12 0.84
sTfR (mg/L) 86 89 2.0 0.92
Ferritin (µg/L) 87 95 30 0.92
TfR-F Index 92 94 1.49 0.97
in the IDA group compared to the ACD group (Table 1).
Soluble transferrin receptor and TIBC were signiﬁcantly
higher in the IDA group, whereas there was no diﬀerence for
CRP (Table 1). The best cut-oﬀ point for CHr was 30.5pg,
corresponding to a sensitivity of 93% and a speciﬁcity
of 69% for IDA, respectively. For MCH, a sensitivity of
93% and a speciﬁcity of 86%, respectively, corresponds to
an optimal cut-oﬀ of 28.5pg. Sensitivity, speciﬁcity, cut-
oﬀ points, and ROC area data for CHr, MCH, ferritin,
transferrin saturation, sTfR, and TfR-F Index are presented
in Table 2.
The discrimination between IDA and ACD is seldom
straightforward in elderly hospitalized anemic patients suf-
fering from pathologic conditions such as cancer, infections,
or inﬂammatory diseases, since biochemical iron status is
inﬂuenced by acute-phase responses [1]. Several authors
[4, 9–11]h a v es u g g e s t e dd i ﬀerent noninvasive tests or
combinations of tests, such as CHr, sTfR, and TfR-F Index as
alternatives to bone marrow iron staining for discriminationAnemia 3
between IDA and ACD. The aim of this study was to
evaluate sensitivity and speciﬁcity for CHr compared to
other hematimetric and biochemical iron tests, in particular
MCH, when screening for iron deﬁciency in elderly hospi-
talized anemic patients. A comparison between hemoglobin
content in reticulocytes (CHr) and erythrocytes (MCH)
is especially interesting since the content of reticulocytes
reﬂects iron availability for erythropoiesis during the last 1-
2 days in contrast to the latter, the content of which reﬂects
bone marrow iron availability for the entire lifespan of the
erythrocyte, that is, 120 days. The results presented here
suggest that the CHr assay is not superior to analysis of
MCH, ferritin, sTfR, or the TfR-F Index with respect to
sensitivity and speciﬁcity when screening for iron deﬁciency
in a population of elderly hospitalized anemic patients.
Receiver Operating Characteristics analyses provided the
highest AUCROC value for the TfR-F Index, which is in
agreement with previously published data [10, 12]. The
iron-deﬁcient patients in this study were all absolute iron
depleted as determined by bone marrow iron staining, and
it is therefore conceivable that the CHr analysis is superior
to MCH in earlier stages of iron deﬁciency or in FID. Other
studies have shown higher CHr sensitivity and speciﬁcity
for iron deﬁciency anemia or that CHr is superior to MCH
analysis when screening for IDA [6, 8, 13]. This study is
limited by the relatively low number of patients investigated
compared to the other studies discussed here [6, 8, 13].
Furthermore, in contrast to the study by C. Thomas and
L. Thomas [11], the group of patients with pure IDA was
not analyzed separately from those with IDA complicated by
ACD,whichcouldhaveinﬂuencedtheresults.Otherpossible
explanations for these conﬂicting data could be that the
populations studied were diﬀerent from the one investigated
in this study or that only one of them used the absence of
bone marrow iron as the gold standard criterion for IDA.
4. Conclusion
Analysis of reticulocyte hemoglobin content is not superior
to analysis of the hemoglobin content of the mature erythro-
cyte (MCH) when screening for iron deﬁciency in elderly
anemic hospitalized patients.
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